Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.

Molecular cancer therapeutics - 1 Sept 2020

Gilardi Mara, Wang Zhiyong, Proietto Marco, Chillà Anastasia, Calleja-Valera Juan Luis, Goto Yusuke, Vanoni Marco, Janes Matthew R, Mikulski Zbigniew, Gualberto Antonio, Molinolo Alfredo A, Ferrara Napoleone, Gutkind J Silvio, Burrows Francis

Abstract excerpt

Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase (FTase). FTase catalyzes the posttranslational attachment of farnesyl groups to signaling proteins that are required for localization to cell membranes. Although all RAS isoforms are FTase substrates, only HRAS is exclusively dependent upon farnesylation, raising the possibility that HRAS-mutant tumors might be susceptible to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkyl and Aryl Transferases
Share to Head and Neck Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Precision Medicine

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinolones

Share to Sequence Analysis, RNA

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 32727882
DOI: 10.1158/1535-7163.MCT-19-0958
PMCID: PMC7484242

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.PMID 32727882Read ↗

Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.Semantic proximity Read ↗

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.Semantic proximity Read ↗

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcomaSemantic proximity Read ↗

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors.Semantic proximity Read ↗

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.Semantic proximity Read ↗

Evolving therapies: farnesyltransferase inhibitors.Semantic proximity Read ↗

A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.Semantic proximity Read ↗

Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.Semantic proximity Read ↗

Precision drugging of the MAPK pathway in head and neck cancerSemantic proximity Read ↗

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.Semantic proximity Read ↗

New tricks for human farnesyltransferase inhibitor: cancer and beyondSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.